Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 846,877,440
  • Shares Outstanding, K 950,405
  • Annual Sales, $ 34,124 M
  • Annual Income, $ 5,240 M
  • 60-Month Beta 0.42
  • Price/Sales 24.63
  • Price/Cash Flow 116.17
  • Price/Book 61.75
Trade LLY with:

Options Overview Details

View History
  • Implied Volatility 38.98% ( +1.02%)
  • Historical Volatility 20.87%
  • IV Percentile 96%
  • IV Rank 50.65%
  • IV High 55.08% on 08/05/24
  • IV Low 22.46% on 06/28/24
  • Put/Call Vol Ratio 1.03
  • Today's Volume 28,673
  • Volume Avg (30-Day) 37,706
  • Put/Call OI Ratio 0.94
  • Today's Open Interest 302,340
  • Open Int (30-Day) 297,460

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 4.54
  • Number of Estimates 9
  • High Estimate 5.01
  • Low Estimate 4.27
  • Prior Year 0.10
  • Growth Rate Est. (year over year) +4,440.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
858.81 +3.11%
on 09/30/24
954.00 -7.18%
on 09/04/24
-70.98 (-7.42%)
since 09/03/24
3-Month
747.55 +18.46%
on 08/05/24
972.53 -8.94%
on 08/22/24
-12.55 (-1.40%)
since 07/03/24
52-Week
523.63 +69.12%
on 10/04/23
972.53 -8.94%
on 08/22/24
+360.36 (+68.62%)
since 10/03/23

Most Recent Stories

More News
US Port Strike Threatens Supply of Popular Weight-Loss Drugs Ozempic, Wegovy, Mounjaro, and Zepbound

The ongoing US port strike on the East and Gulf coasts is causing significant disruptions to pharmaceutical supply chains, particularly for the popular weight-loss drugs Wegovy, Ozempic, Mounjaro, and...

NVO : 115.08 (-1.20%)
LLY : 885.55 (-0.62%)
Eli Lilly to Invest $4.5B for New Manufacturing & Research Plant

Eli Lilly and Company LLY announced a significant $4.5 billion investment for the establishment of the Lilly Medicine Foundry in Indiana to advance drug production and innovation. This facility will enable...

AZN : 77.93 (-2.07%)
NVO : 115.08 (-1.20%)
LLY : 885.55 (-0.62%)
SNY : 55.54 (-1.26%)
This IPO Biotech Stock Could Be the Next Eli Lilly

BioAge has its eyes on a handful of truly gargantuan markets.

BIOA : 20.86 (+5.73%)
LLY : 885.55 (-0.62%)
Drugmaker Lilly slates another $4.5B for manufacturing and drug development improvements

Eli Lilly is pouring another $4.5 billion into expanding drug manufacturing and development

LLY : 885.55 (-0.62%)
3 Momentum Trades Too Good Pass Up

Check out these three stocks each up over 60% in the past twelve months. Their strong paths for growth can help keep their momentum stories going.

INTC : 22.26 (-0.58%)
NVO : 115.08 (-1.20%)
LLY : 885.55 (-0.62%)
SPY : 567.82 (-0.18%)
ISRG : 479.63 (-1.44%)
DELL : 115.67 (+1.95%)
MTUM.BZ : N/A (N/A)
Should You Buy AbbVie Stock After Recent Parkinson's Study Success?

Last week, AbbVie ABBV announced that a pivotal phase III study evaluating pipeline candidate tavapadon for treating early Parkinson's disease met the primary endpoint. The candidate was added to AbbVie’s...

NVO : 115.08 (-1.20%)
GMAB : 23.40 (-1.22%)
LLY : 885.55 (-0.62%)
ABBV : 195.45 (-0.70%)
Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors

Roche RHHBY announced an asset purchase agreement with clinical-stage biotechnology company Regor Therapeutics.Per the agreement, Roche’s Genentech will acquire Regor’s portfolio of next-generation...

NVO : 115.08 (-1.20%)
LLY : 885.55 (-0.62%)
NVS : 113.77 (-0.61%)
RHHBY : 38.2800 (-2.02%)
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition

NetworkNewsWire Editorial Coverage : Alzheimer’s disease (“AD”) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received U.S. Food and Drug...

ANVS : 8.02 (-4.07%)
NVO : 115.08 (-1.20%)
LLY : 885.55 (-0.62%)
ABBV : 195.45 (-0.70%)
PFE : 28.34 (-0.94%)
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition

EQNX::TICKER_START (NYSE:ANVS),(NYSE:LLY),(NYSE:PFE),(NYSE:NVO),(NASDAQ:ABBV) EQNX::TICKER_END

ANVS : 8.02 (-4.07%)
NVO : 115.08 (-1.20%)
LLY : 885.55 (-0.62%)
ABBV : 195.45 (-0.70%)
PFE : 28.34 (-0.94%)
Why Viking Therapeutics Stock Topped the Market Today

An analyst waxed bullish on the company's leading pipeline program.

VKTX : 64.11 (-0.90%)
MS : 104.57 (+0.05%)
LLY : 885.55 (-0.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 902.53
2nd Resistance Point 897.26
1st Resistance Point 891.41
Last Price 885.55
1st Support Level 880.29
2nd Support Level 875.02
3rd Support Level 869.17

See More

52-Week High 972.53
Last Price 885.55
Fibonacci 61.8% 801.05
Fibonacci 50% 748.08
Fibonacci 38.2% 695.11
52-Week Low 523.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar